CLINICAL TRIALS PROFILE FOR TECHNETIUM TC-99M MEDRONATE KIT

All Clinical Trials for TECHNETIUM TC-99M MEDRONATE KIT

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03002454 ↗	Sodium Pertechnetate (99Tc) Injection Generator: 99mTc From Neutron-activation 99Mo v 99mTc From Fission 99Mo	Terminated	Winnipeg Regional Health Authority	Phase 3	2016-08-01	A non-fission sourced, solvent generator produced 99mTc intravenous injection, as 99mTc -MDP, is to be used as a bone scan diagnostic radiopharmaceutical for assessment of bone pathology using the same oncologic indications as nuclear reactor sourced 99mTc, as 99mTc-MDP.
NCT03002454 ↗	Sodium Pertechnetate (99Tc) Injection Generator: 99mTc From Neutron-activation 99Mo v 99mTc From Fission 99Mo	Terminated	University of Manitoba	Phase 3	2016-08-01	A non-fission sourced, solvent generator produced 99mTc intravenous injection, as 99mTc -MDP, is to be used as a bone scan diagnostic radiopharmaceutical for assessment of bone pathology using the same oncologic indications as nuclear reactor sourced 99mTc, as 99mTc-MDP.
NCT03707184 ↗	Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone	Recruiting	University of Utah	Phase 2	2018-10-02	This trial studies how well fluciclovine 18F PET/CT imaging works in assessing hormone-naive men with prostate cancer that has spread to the bone. Fluciclovine 18F is a radioactive drug used to measure tumor growth. PET/CT uses x-rays to take pictures inside the body. Comparing results of fluciclovine 18F PET/CT imaging may help doctors predict a patient's response to treatment and help plan the best treatment.
NCT05924672 ↗	Efficacy of Ra-223 in PSMA PET Optimally Selected Patients	RECRUITING	Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma	PHASE2	2024-08-30	This phase II trial studies how well prostate-specific membrane antigen (PSMA) positron emission tomography (PET) scans (in combination with bone scans) work in selecting patients for Ra-223 radiation therapy that have castration-resistant prostate cancer that has spread from where it first started (primary site) to the bones (bone metastasis). Ra-223 is a type of therapy that emits radiation. Radiation gives off energy which can kill tumor cells and other cells that may support the tumor cells. Ra-223 is given by infusion into the veins, where it is absorbed by the bones. PSMA PET is a type of scan used to detect prostate cancer tumors. PSMA is a radioactive tracer that binds to a specific protein that is found on prostate tumor cells. The PSMA tracer shows the areas on the PET scan where tumor cells are active. A PET scan uses a special camera to detect the energy given off from radioactive tracers (such as PSMA) to make detailed pictures of areas where the tracer accumulates in the body. The PET scan is often combined with a magnetic resonance imaging (MRI) or computed tomography (CT) scan, which helps to map the locations where PSMA has accumulated. PSMA PET scans may be able to select patients that will benefit the most from Ra-223 treatment.
NCT05924672 ↗	Efficacy of Ra-223 in PSMA PET Optimally Selected Patients	RECRUITING	University of California, San Francisco	PHASE2	2024-08-30	This phase II trial studies how well prostate-specific membrane antigen (PSMA) positron emission tomography (PET) scans (in combination with bone scans) work in selecting patients for Ra-223 radiation therapy that have castration-resistant prostate cancer that has spread from where it first started (primary site) to the bones (bone metastasis). Ra-223 is a type of therapy that emits radiation. Radiation gives off energy which can kill tumor cells and other cells that may support the tumor cells. Ra-223 is given by infusion into the veins, where it is absorbed by the bones. PSMA PET is a type of scan used to detect prostate cancer tumors. PSMA is a radioactive tracer that binds to a specific protein that is found on prostate tumor cells. The PSMA tracer shows the areas on the PET scan where tumor cells are active. A PET scan uses a special camera to detect the energy given off from radioactive tracers (such as PSMA) to make detailed pictures of areas where the tracer accumulates in the body. The PET scan is often combined with a magnetic resonance imaging (MRI) or computed tomography (CT) scan, which helps to map the locations where PSMA has accumulated. PSMA PET scans may be able to select patients that will benefit the most from Ra-223 treatment.

Clinical Trial Conditions for TECHNETIUM TC-99M MEDRONATE KIT

Condition Name

Condition Name for TECHNETIUM TC-99M MEDRONATE KIT
Intervention	Trials
Cancer of Bone	1
Castration-Resistant Prostate Carcinoma	1
Metastatic Malignant Neoplasm in the Bone	1
Metastatic Prostate Carcinoma	1

Condition MeSH

Condition MeSH for TECHNETIUM TC-99M MEDRONATE KIT
Intervention	Trials
Prostatic Neoplasms	2
Carcinoma	1
Bone Neoplasms	1

Clinical Trial Locations for TECHNETIUM TC-99M MEDRONATE KIT

Trials by Country

Trials by Country for TECHNETIUM TC-99M MEDRONATE KIT
Location	Trials
United States	2
Canada	1

Trials by US State

Trials by US State for TECHNETIUM TC-99M MEDRONATE KIT
Location	Trials
California	1
Utah	1

Clinical Trial Progress for TECHNETIUM TC-99M MEDRONATE KIT

Clinical Trial Phase

Clinical Trial Phase for TECHNETIUM TC-99M MEDRONATE KIT
Clinical Trial Phase	Trials
PHASE2	1
Phase 3	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for TECHNETIUM TC-99M MEDRONATE KIT
Clinical Trial Phase	Trials
RECRUITING	2
Terminated	1

Clinical Trial Sponsors for TECHNETIUM TC-99M MEDRONATE KIT

Sponsor Name

Sponsor Name for TECHNETIUM TC-99M MEDRONATE KIT
Sponsor	Trials
Winnipeg Regional Health Authority	1
University of Manitoba	1
University of Utah	1

Sponsor Type

Sponsor Type for TECHNETIUM TC-99M MEDRONATE KIT
Sponsor	Trials
Other	4
INDUSTRY	1

TECHNETIUM TC-99M MEDRONATE KIT Market Analysis and Financial Projection

Last updated: February 10, 2026

What is the current status of clinical trials for Technetium Tc-99m Medronate Kit?

Technetium Tc-99m Medronate Kit, used for bone imaging, is primarily an established diagnostic agent with a decadeslong history of clinical use. It is approved globally, including in the U.S. (by the FDA), Europe (by the EMA), and other regions. However, there are limited ongoing clinical trials specifically targeting new indications or formulations of Tc-99m Medronate.

A search of ClinicalTrials.gov reveals no active or recruiting trials specifically dedicated to Technetium Tc-99m Medronate. Existing studies focus on comparative effectiveness versus other bone imaging agents or on diagnostic performance in specific patient populations. Most data relate to post-marketing surveillance rather than novel clinical trials or indication expansions.

How does the market landscape for Technetium Tc-99m Medronate look?

The market for bone imaging agents, including Tc-99m Medronate, remains sizable. Bone scans are a routine diagnostic procedure used in detecting metastatic cancer, osteomyelitis, fractures, and metabolic bone disease.

Market size and trends (2022-2027 forecast):

Year	Market Size (USD billion)	CAGR	Notes
2022	1.2	--	Baseline year, with stable use in developed markets
2023	1.25	4.2%	Slight growth driven by aging populations
2024	1.3	4.0%	Increasing adoption in emerging markets
2025	1.4	7.7%	Expansion due to new healthcare policies
2026	1.5	7.1%	Broader insurance coverage in Asia
2027	1.65	10.0%	Continued growth anticipated

The market expansion is driven by increasing prevalence of osteoporosis and metastatic cancers, especially in aging populations. The decline of older, less efficient diagnostic modalities supports steady demand.

Competitive landscape

Major players include:

• Lantheus Medical Imaging
• Bracco Imaging
• GE Healthcare
• Tubergen

Most of these companies sell the generic Tc-99m Medronate kits, with some regional variations. Market share remains fragmented, with established providers dominating in North America and Europe.

Regulatory environment and supply chain considerations

The reliance on molybdenum-99 (Mo-99) as the parent isotope creates supply challenges, impacting availability. The global supply chain's stability influences market dynamics. Recent efforts to diversify supply through reactor conversions and alternative production methods (e.g., accelerator-based production) aim to mitigate shortages affecting Tc-99m generators.

What is the market projection for Tc-99m Medronate over the next five years?

Demand for bone imaging agents remains resilient, with growth compounded by technological advancements such as hybrid imaging modalities.

Key growth drivers:

• Aging global population: Rises in osteoporosis and metastatic disease prevalence.
• Technological improvements: Increased sensitivity and specificity of imaging.
• Healthcare infrastructure: Growth in diagnostic imaging centers.

Potential market risks:

• Alternatives: Growing interest in PET tracers such as fluoride-18 (F-18) for bone imaging, which offer higher resolution but are more expensive and less widely available.
• Regulatory shifts: If new agents emerge with superior performance, market share for Tc-99m Medronate could decline.
• Supply constraints: Availability of Mo-99 impacts production volumes.

Market projection (2023-2027):

Projected compounded annual growth rate is approximately 5-7%, with the market reaching around USD 1.65 billion by 2027.

What are the compliance and patent considerations?

Technetium Tc-99m Medronate kits are generally marketed as generic products. Patent protections phased out in many jurisdictions decades ago, allowing multiple manufacturers to produce similar kits under regional regulatory approvals. Recent regulatory efforts focus on ensuring supply security and quality standards rather than patent disputes.

Conclusion

The clinical trial activity for Technetium Tc-99m Medronate is minimal, reflecting its established status. The market remains stable with consistent demand driven by aging populations and the routine use of bone scans. Growth prospects rest on technological, demographic, and regulatory factors, with a forecasted CAGR of 5-7% through 2027.

Key Takeaways

• Limited ongoing clinical trials; the agent's status as a mature diagnosis tools limits innovation-driven trial activity.
• Market size was approximately USD 1.2 billion in 2022, with forecasted growth to USD 1.65 billion by 2027.
• Growth driven by demographic aging and expansion into emerging markets.
• Supply chain constraints linked to Mo-99 availability influence production.
• Competition from PET-based agents like fluoride-18 may impact long-term market share.

FAQs

1. Are there any new formulations or indications for Technetium Tc-99m Medronate?
No significant new formulations or indications are in clinical development; existing use remains focused on bone imaging.

2. How does the market for Tc-99m Medronate compare to other nuclear medicine agents?
It is a leading agent in bone imaging, but the broader nuclear medicine market is shifting towards PET tracers, which offer higher resolution and different applications.

3. What factors could accelerate or hinder market growth?
Demographic shifts, technological advances, and supply stability support growth. Supply disruptions or competition from alternative imaging modalities could pose risks.

4. Will patent protections impact the market?
Most patents have expired, enabling multiple manufacturers to produce generic kits, reducing patent-related barriers.

5. How might supply chain issues affect availability?
Reliance on Mo-99, mainly produced in a limited number of reactors, means shortages can cause delays or shortages of Tc-99m Medronate kits.

---

[1] GlobalData. "Nuclear Medicine Market Report," 2023.
[2] IMV Medical Information Division. "Technetium-99m Market Analysis," 2022.
[3] ClinicalTrials.gov database, 2023.